Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system in gastric parietal cells. It is available in delayed-release oral tablets and IV formulations.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Short-term treatment of GERD symptoms.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg PO/IV once daily for 8 weeks. May repeat for another 8-week course if needed.
* **Maintenance of Healing:** 40 mg PO once daily.
* **Hypersecretory Conditions:** 40 mg PO twice daily; dosage may be titrated up to 240 mg/day based on patient needs.
* **IV Bolus:** 40 mg via IV injection (over 15 minutes) or IV infusion (over 15 minutes).
## Pediatric Dosing
* **GERD (Erosive Esophagitis):**
* **5 years to <17 years:** Weight $\ge$ 15 kg to <40 kg: 20 mg once daily. Weight $\ge$ 40 kg: 40 mg once daily. Duration up to 8 weeks.
* **IV Dosing:** Not universally established for pediatric populations; use follows institutional protocols.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Use with caution; monitor liver enzymes. Severe impairment may require dose reduction (e.g., 20 mg daily or every other day).
## Contraindications
* Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole).
* Concurrent use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, injection site reactions.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, and increased risk of bone fractures (osteoporosis-related).
## Key Drug Interactions
* **pH-dependent drugs:** Reduced absorption of atazanavir, nelfinavir, and certain azole antifungals (e.g., ketoconazole).
* **Methotrexate:** Potential for increased methotrexate levels/toxicity, especially in high-dose therapy.
* **Warfarin:** Potential for increased INR/prothrombin time; monitor closely.
## Monitoring
* Monitor for signs of hypomagnesemia (tremors, palpitations) during long-term therapy.
* Monitor magnesium levels periodically if on therapy >1 year or with concomitant digoxin/diuretics.
* Monitor for symptoms of CDAD (persistent diarrhea).
* Evaluate need for ongoing therapy; deprescribe if no clear indication exists.
## Clinical Pearls
* **Administration:** Tablets should be swallowed whole; do not crush or chew. IV formulation requires an in-line filter (1.2 micron).
* **Timing:** Administer oral doses 30–60 minutes before a meal for optimal absorption.
* **Uncertainty:** PPIs are frequently over-prescribed; reassess the necessity of acid suppression regularly, particularly in hospitalized patients without clear GI bleed risks. Continuous use beyond 8 weeks should be justified by clinical findings.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice and institutional guidelines vary. Always consult the most current official prescribing information (package insert) and official drug databases (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
